Nasdaq:US$15.15 (+0.04) | HKEX:HK$24.10 (-0.10) | AIM:£2.41 (+0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer